Kim Kelderman - Nov 1, 2023 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Chief Operating Officer
Signature
/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.
Stock symbol
TECH
Transactions as of
Nov 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/5/2024, 06:33 PM
Previous filing
Aug 28, 2023
Next filing
Aug 2, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TECH Common Stock 35.4K Nov 1, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Restricted Stock Units Award $0 +9.42K $0.00 9.42K Feb 1, 2024 Common Stock 9.42K Direct F3, F8
transaction TECH Stock Options (Right to Buy) Award $0 +25.9K $0.00 25.9K Feb 1, 2024 Common Stock 25.9K $68.54 Direct F8
transaction TECH Stock Options (Right to Buy) Award $0 +51.9K $0.00 51.9K Feb 1, 2024 Common Stock 51.9K $68.54 Direct F11
holding TECH Stock Option (Right to Buy) 27.4K Nov 1, 2023 Common Stock 27.4K $37.70 Direct F1
holding TECH Stock Option (Right to Buy) 84.3K Nov 1, 2023 Common Stock 84.3K $44.33 Direct F1
holding TECH Stock Option (Right to Buy) 110K Nov 1, 2023 Common Stock 110K $47.60 Direct F1
holding TECH Stock Option (Right to Buy) 69.3K Nov 1, 2023 Common Stock 69.3K $66.97 Direct F1
holding TECH Stock Option (Right to Buy) 48K Nov 1, 2023 Common Stock 48K $66.97 Direct F2
holding TECH Restricted Stock Units 4.98K Nov 1, 2023 Common Stock 4.98K Direct F3, F4
holding TECH Stock Option (Right to Buy) 19.5K Nov 1, 2023 Common Stock 19.5K $120.46 Direct F4
holding TECH Stock Option (Right to Buy) 25.9K Nov 1, 2023 Common stock 25.9K $120.46 Direct F5
holding TECH Restricted Stock Units 6.98K Nov 1, 2023 Common Stock 6.98K Direct F3, F6
holding TECH Stock Options (Right to Buy) 21.7K Nov 1, 2023 Common Stock 21.7K $94.52 Direct F6
holding TECH Stock Options (Right to Buy) 28.9K Nov 1, 2023 Common Stock 28.9K $94.52 Direct F7
holding TECH Restricted Stock Units 8.87K Nov 1, 2023 Common Stock 8.87K Direct F3, F8
holding TECH Stock Options (Right to Buy) 23.9K Nov 1, 2023 Common Stock 23.9K $84.61 Direct F8
holding TECH Stock Options (Right to Buy) 29.4K Nov 1, 2023 Common Stock 29.4K $84.61 Direct F9
holding TECH Stock Options (Right to Buy) 38.3K Nov 1, 2023 Common Stock 38.3K $52.83 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully exercisable.
F2 Options to purchase 35,964 shares are vested. Options to purchase 11,988 shares vest on 8/5/2024.
F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F4 Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F5 Options to purchase 12,972 shares are vested. Options to purchase 6,488 shares vest on 8/6/2024 and options to purchase 6,484 shares vest on 8/6/2025.
F6 Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F7 Options to purchase 7,236 shares are vested. Options to purchase 7,236 shares vest on each of 8/15/2024 and 8/15/2026 and options to purchase 7,232 shares vest on 8/15/2025.
F8 Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F9 Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
F10 Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
F11 Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.